Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
13.03
-1.92 (-12.84%)
At close: Apr 28, 2026, 4:00 PM EDT
13.27
+0.24 (1.84%)
After-hours: Apr 28, 2026, 7:54 PM EDT
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 18.9, with a low estimate of 10 and a high estimate of 22. The average target predicts an increase of 45.05% from the current stock price of 13.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Relay Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 3 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 7 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $13 → $22 | Strong Buy | Maintains | $13 → $22 | +68.84% | Apr 28, 2026 |
| Citizens | Citizens | Buy Maintains $17 → $19 | Buy | Maintains | $17 → $19 | +45.82% | Apr 28, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $17 → $21 | Buy | Maintains | $17 → $21 | +61.17% | Apr 28, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $18 | Buy | Maintains | $14 → $18 | +38.14% | Apr 28, 2026 |
| Jones Trading | Jones Trading | Hold Initiates $18 | Hold | Initiates | $18 | +38.14% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
4.10M
from 15.36M
Decreased by -73.28%
Revenue Next Year
17.40M
from 4.10M
Increased by 324.03%
EPS This Year
-1.56
from -1.61
EPS Next Year
-1.54
from -1.56
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 15.8M | 75.0M | ||||||
| Avg | 4.1M | 17.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.6% | 1,727.2% | ||||||
| Avg | -73.3% | 324.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.31 | -1.26 | ||||||
| Avg | -1.56 | -1.54 | ||||||
| Low | -1.92 | -2.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.